Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: A single-center, long-term follow-up

Haematologica

Volumn 99, Issue 5, 2014, Pages 937-944

  Ghanima, Waleed ^a,b   Geyer, Julia Turbiner ^b   Lee, Christina S ^b   Boiocchi, Leonardo ^b   Imahiyerobo, Allison A ^b   Orazi, Attilio ^b   Bussel, James B ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVATROMBOPAG; COLLAGEN; ELTROMBOPAG; HEMOSTATIC AGENT; RETICULIN; ROMIPLOSTIM; SHIONOGI AGENT; THROMBOPOIETIN RECEPTOR AGONIST; UNCLASSIFIED DRUG; THROMBOPOIETIN RECEPTOR;

ADOLESCENT; ADULT; AGE; ARTICLE; BONE MARROW BIOPSY; CHROMOSOME ANALYSIS; COMPARATIVE STUDY; CYTOGENETICS; DISEASE DURATION; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TURNER SYNDROME; Y CHROMOSOME; AGONISTS; BIOPSY; BONE MARROW; CASE CONTROL STUDY; CHILD; COMPLICATION; INFANT; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; PRIMARY MYELOFIBROSIS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; SPLENOMEGALY; YOUNG ADULT;

ADOLESCENT; ADULT; BIOPSY; BONE MARROW; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CYTOGENETIC ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOPHENOTYPING; INFANT; MALE; MIDDLE AGED; PLATELET COUNT; PRIMARY MYELOFIBROSIS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, THROMBOPOIETIN; SPLENOMEGALY; YOUNG ADULT;

EID: 84898916955     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.098921     Document Type: Article

References (23)

1. Kuter DJ. Biology and chemistry of thrombopoietic agents. Semin Hematol. 2010; 47(3): 243-8.
2. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009; 113(26): 6511-21.
3. Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, doubleblind, placebo-controlled trial. Lancet. 2009; 373(9664): 641-8.
4. Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006; 355(16): 1672-81.
5. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007; 357(22): 2237-47.
6. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008; 371(9610): 395-403.
7. Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010; 363 (20): 1889-99.
8. Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011; 377(9763): 393-402.
9. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009; 113(10): 2161-71.
10. Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood. 2002; 100(10): 3495-503.
11. Kuter DJ, Mufti GJ, Bain BJ, Hasserjian RP, Davis W, Rutstein M. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood. 2009; 114(18): 3748-56.
12. Boiocchi L, Orazi A, Ghanima W, Arabadjief M, Bussel JB, Geyer JT. Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities. Mod Pathol. 2012; 25(1): 65-74.
13. Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013; 121(3): 537-45.
14. Kuter DJ, Bain B, Mufti G, Bagg A, Hasserjian RP. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol. 2007; 139(3): 351-62.
15. Kuter DJ, Gminski DM, Rosenberg RD. Transforming growth factor beta inhibits megakaryocyte growth and endomitosis. Blood. 1992; 79(3): 619-26.
16. Ghanima W, Junker P, Hasselbalch HC, Boiocchi L, Geyer JT, Feng X, et al. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents. Br J Haematol. 2011; 155(2): 248-55.
17. Ghanima W, Bussel JB. Thrombopoietic agents in immune thrombocytopenia. Semin Hematol. 2010; 47(3): 258-65.
18. Kantarjian H, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, et al. Treatment with the thrombopoietin (TPO)-receptor agonist romiplostim in thrombocytopenic patients (Pts) with low or intermediate-1 (int-1) risk myelodysplastic syndrome (MDS): follow-up AML and survival results of a randomized, double-blind, placebo (PBO)-controlled study. Blood. 2012: 120; 421.
19. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005; 90(8): 1128-32.
20. Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol. 2013; 161(3): 411-23.
21. Brynes RKO, Wong A, Bakshi RS, Bailey K, Brainsky CK. A longitudinal prospective study evaluating the effects of eltrombopag treatment on bone marrow in patients with chronic immune thrombocytopenia: interim analysis at 1 year. Blood. 2012: Abstract 2195.
22. Bauermeister DE. Quantitation of bone marrow reticulin--a normal range. Am J Clin Pathol. 1971; 56(1): 24-31.
23. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011; 29(6): 761-70.